Théa is proud to announce the launch of Vevizye®, a breakthrough treatment for the treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes. This innovative therapy strengthens Théa’s already robust portfolio of dry eye solutions.